We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AXA Diagnostics Named Exclusive Distributor for Rosetta Genomics' microRNA-based Assays in Italy

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "AXA Diagnostics Named Exclusive Distributor for Rosetta Genomics' microRNA-based Assays in Italy"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Rosetta Genomics, Ltd. and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

Under the terms of the agreement, AXA will market Rosetta Genomics’ miRview™ tests in Italy. Samples will be sent from Italy to Rosetta Genomics’ CLIA-laboratory in Philadelphia for analysis. The terms of the deal were not disclosed.

“This latest distribution agreement with AXA Diagnostics marks Rosetta Genomics’ entry into Europe, and we are excited to have AXA as our first partner in this region,” noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. “We believe that there is significant need for our miRview™ tests in Italy, as well as worldwide, and that AXA is the right partner to bring these tests to cancer patients in Italy. As we have previously mentioned, we are continuously expanding our global distribution network, and believe that by the end of the year our tests will be available in other regions as well.”

Silvio Furino, President of AXA Diagnostics, said, “We are excited about our new relationship with Rosetta Genomics. We expect that these novel molecular diagnostic tests will provide improved diagnoses for cancer patients in Italy and that physicians will now be able to provide personalized medicine and customized treatment. This new era of high-quality healthcare has the potential to make better medical outcomes possible.”

The following tests will be distributed by AXA Diagnostics:

miRview™ mets – This test can identify the primary tumor site in patients presenting with metastatic cancer, as well as in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP).

miRview™ squamous – Using a single microRNA, miRview™ squamous differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients.

miRview™ meso – This test leverages microRNA’s high specificity as biomarkers to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung.